Erschienen in:
09.10.2018 | ASO Author Reflections
ASO Author Reflections: Improving Patient Selection for Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy
verfasst von:
Olga Kantor, MD, Ted A. James, MD, MS, FACS
Erschienen in:
Annals of Surgical Oncology
|
Sonderheft 3/2018
Einloggen, um Zugang zu erhalten
Excerpt
The accuracy of sentinel lymph node biopsy (SLNB) after neoadjuvant chemotherapy (NCT) for clinically node-positive breast cancer can be indistinct due to the increased rates of false-negative findings with this approach.
1 According to clinical trial data, approximately 30–40% of patients will achieve an axillary pathologic complete response to NCT, obviating the need for axillary lymph node dissection (ALND) in these cases.
2 A number of recent clinical trials evaluating the feasibility of SLNB after NCT demonstrate that in addition to using dual tracers, obtaining multiple sentinel nodes (including the clipped node from the initial positive biopsy) may help to reduce the false-negative rate to acceptable levels.
1–4 However, identification of suitable candidates for this approach can be challenging. The authors’ goal was to develop a predictive model based on clinical factors to facilitate patient selection and support the appropriate use of SLNB after NCT.
5 …
